Summit Global Investments’ holdings in Neurocrine Biosciences were worth $5,075,000 at the end of the most recent reporting period. Get Neurocrine Biosciences alerts:Insider ActivityIn other Neurocrine Biosciences news, Director Leslie V. Norwalk sold 5,000 shares of Neurocrine Biosciences stock in a transaction dated Monday, December 15th. View Our Latest Analysis on Neurocrine BiosciencesNeurocrine Biosciences Stock Up 2.5%Shares of NASDAQ NBIX opened at $137.96 on Friday. Neurocrine Biosciences Company Profile(Free Report)Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.